ARTICLE | Clinical News
A4250 regulatory update
October 31, 2016 7:00 AM UTC
EMA granted PRIority MEdicines (PRIME) designation to A4250 from Albireo to treat progressive familial intrahepatic cholestasis. A4250 is in Phase II testing for pediatric chronic cholestasis. The pro...